Beyond anxiety and agitation: A clinical approach to akathisia

Australian Family Physician

Volumn 46, Issue 5, 2017, Pages 296-298

  Tachere, Richardson Oghoteru ^a   Modirrousta, Mandana ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; BUSPIRONE; CINNARIZINE; DILTIAZEM; METHYLDOPA; NEUROLEPTIC AGENT; RESERPINE;

ADULT; ANXIETY; CASE REPORT; COMPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMAN; PSYCHOMOTOR AGITATION; SUICIDAL IDEATION;

ADULT; ANTIDEPRESSIVE AGENTS; ANTIEMETICS; ANTIPSYCHOTIC AGENTS; ANXIETY; BUSPIRONE; CINNARIZINE; DILTIAZEM; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; METHYLDOPA; PSYCHOMOTOR AGITATION; RESERPINE; SUICIDAL IDEATION;

EID: 85018343961     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sadock BJ, Sadock VA, Ruiz P. Kaplan and Sadock's synopsis of psychiatry, behavioral sciences/clinical psychiatry. 11th edn. Philadelphia: Wolters Kluwer, 2015.
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn. Washington, DC: American Psychiatric Publishing, 2013.
3. Gardner DM, Teehan MD. Antipsychotics and their side effects. Cambridge: Cambridge University Press, 2011.
4. Forcen FE. Akathisia: Is restlessness a primary condition or an adverse drug effect? Keep a discerning eye out for this adverse effect of antipsychotics and other drugs. Current Psychiatry 2015;14(1):14-18.
5. Kane JM, Fleischhacker WW, Hansen L, Perlis R, Pikalov A, Assunção-Talbott S. Akathisia: An updated review focusing on secondgeneration antipsychotics. J Clin Psychiatry 2009;70(5):627-43.
6. Sachdev P, Loneragan C. The present status of akathisia. J Nerv Ment Dis 1991;179(7):381-89.
7. Poyurovsky M, Fuchs C, Schneidman M, Weizman A. Treatment of neuroleptic-induced akathisia with the 5-HT, antagonist mianserin-Double-blind, placebo-controlled study. Br J Psychiatry 1999;174(3):238-42.
8. Riesselman A, El-Mallakh, RS. Akathisia with azithromycin. Ann Pharmacother 2015;49(5):609.
9. Dag E, Gokce B, Buturak SV, Tiryaki D, Erdemoglu AK. Pregabalin-induced akathisia. Ann Pharmacother 2013;47(4):592-93.
10. Iqbal N, Lambert T, Masand P. Akathisia: Problem of history or concern of today. CNS Spectr 2007;12(9S14):1-13.
11. Berna F, Misdrahi D, Boyer L. et al. Akathisia: Prevalence and risk factors in a communitydwelling sample of patients with schizophrenia. Results from the FACE-SZ dataset. Schizophrenia Research 2015;169(1-3):255-61.
12. Weiden P, Mann JJ, Haase G, Mattson M, Frances A. Clinical non-recognition of neurolepticinduced movement disorders: A cautionary study. Am J Psychiatry 1987;144(9):1148-53.
13. Hirose, S. The causes of underdiagnosing akathisia. Schizophrenia Bulletin 2003;29(3):547-58.
14. Sachdev P. Research diagnostic criteria for druginduced akathisia: Conceptualization, rationale and proposal. Psychopharmacology 1994;114(1):181-86.
15. Barnes TRE, Braude WM. Akathisia variants and tardive dyskinesia. Arch Gen Psychiatry 1985;42(9):874-78.
16. Kumar R, Sachdev PS. Akathisia and secondgeneration antipsychotic drugs. Curr Opin Psychiatry 2009;22(3):293-99.
17. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 1980;10(1):55-72.
18. Tassin JP, Stinus L, Simon H, et al. Relationship between the locomotor hyperactivity induced by A10 lesions and the destruction of the frontocortical dopaminergic innervation in the rat. Brain Res 1978;141(2):267-81.
19. Lane RM. SSRI-induced extrapyramidal side effects and akathisia: Implications for treatment. J Psychopharmacol 1998;12(2):192-214.
20. Sachdev P. The development of the concept of akathisia: A historical overview. Schizophrenia Research 1995;16(1):33-45.
21. Poyurovsky M. Acute antipsychoticinduced akathisia revisited. Br J Psychiatry 2010;196(2):89-91.
22. Laoutidis ZG, Luckhaus C. 5-HT2A receptor antagonists for the treatment of neurolepticinduced akathisia: A systematic review and meta-analysis. Int J Neuropsychopharmacol. 2014;17(5):823-32.
23. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: A new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo and propranolol controlled trial. Biol Psychiatry 2006;59(11):1071-77.
24. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22(1):73-81.